

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://www.fdi-lab.org) on Apr 11, 2025

## OVCAR-3

RRID:CVCL\_0465

Type: Cell Line

### Proper Citation

(RRID:CVCL\_0465)

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0465](https://web.expasy.org/cellosaurus/CVCL_0465)

**Proper Citation:** (RRID:CVCL\_0465)

**Sex:** Female

**Defining Citation:** [PMID:1348364](#), [PMID:1892748](#), [PMID:2041050](#), [PMID:2307530](#), [PMID:2653399](#), [PMID:3335022](#), [PMID:3930572](#), [PMID:6372095](#), [PMID:6385258](#), [PMID:6604576](#), [PMID:8557231](#), [PMID:9041185](#), [PMID:9698466](#), [PMID:10700174](#), [PMID:11414198](#), [PMID:11793438](#), [PMID:12417041](#), [PMID:12960427](#), [PMID:15748285](#), [PMID:16382445](#), [PMID:17088437](#), [PMID:18277095](#), [PMID:18560578](#), [PMID:19372543](#), [PMID:19926575](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:20215515](#), [PMID:21912889](#), [PMID:22068913](#), [PMID:22328975](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22628656](#), [PMID:22710073](#), [PMID:23172893](#), [PMID:23351415](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24023729](#), [PMID:24279929](#), [PMID:24434149](#), [PMID:24670534](#), [PMID:25230021](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26169745](#), [PMID:26589293](#), [PMID:26972028](#), [PMID:27141528](#), [PMID:27235858](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27561551](#), [PMID:27807467](#), [PMID:28100988](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:32612269](#), [PMID:35839778](#)

**Comments:** Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Secretome proteome analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: O-glycan profiling., Omics: N-glycan profiling., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Genome sequenced., Omics: Fluorescence phenotype profiling., Omics: Exosome proteome analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of:

OCCP ovarian cancer cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

**Category:** Cancer cell line

**Name:** OVCAR-3

**Synonyms:** OvcAR-3, OVCAR 3, OVCAR.3, NIH:OVCAR-3, NIH:OvcAR-3, NIH:OVCAR3, NIH-OVCAR-3, NIHOVCAR3, OVCAR3, OvcAR3

**Cross References:** BTO:BTO\_0000812, CLO:CLO\_0008171, CLO:CLO\_0008279, CLO:CLO\_0051451, EFO:EFO\_0003061, MCCL:MCC:0000363, CLDB:cl3712, CLDB:cl3780, CLDB:cl5237, Abcam:ab275471, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-161, BCRC:60551, BCRJ:0317, BioGRID\_ORCS\_Cell\_line:981, BioSample:SAMN01821585, BioSample:SAMN03471390, BioSample:SAMN05292457, BioSample:SAMN10987888, cancercellines:CVCL\_0465, CCRID:1101HUM-PUMC000362, CCRID:3101HUMTCHu228, CCRID:4201HUM-CCTCC00119, CCTCC:GDC0119, Cell\_Model\_Passport:SIDM00105, ChEMBL-Cells:ChEMBL3307564, ChEMBL-Targets:ChEMBL614213, CLS:300307, Cosmic:687926, Cosmic:688104, Cosmic:755845, Cosmic:809113, Cosmic:844347, Cosmic:845142, Cosmic:875859, Cosmic:897433, Cosmic:905933, Cosmic:906577, Cosmic:920357, Cosmic:924144, Cosmic:927564, Cosmic:949227, Cosmic:974296, Cosmic:991321, Cosmic:1044239, Cosmic:1092623, Cosmic:1093553, Cosmic:1102816, Cosmic:1139222, Cosmic:1175883, Cosmic:1218877, Cosmic:1305312, Cosmic:1312192, Cosmic:1312354, Cosmic:1436033, Cosmic:1482525, Cosmic:1524357, Cosmic:1709250, Cosmic:1998465, Cosmic:2186584, Cosmic-CLP:905933, DepMap:ACH-000001, EGA:EGAS00001000610, EGA:EGAS00001000978, ENCODE:ENCBS419ENC, GDSC:905933, GEO:GSM2122, GEO:GSM50219, GEO:GSM50282, GEO:GSM95463, GEO:GSM185135, GEO:GSM185136, GEO:GSM274703, GEO:GSM313683, GEO:GSM459733, GEO:GSM459741, GEO:GSM645843, GEO:GSM659393, GEO:GSM711708, GEO:GSM743474, GEO:GSM743498, GEO:GSM750817, GEO:GSM784564, GEO:GSM799362, GEO:GSM799363, GEO:GSM799425, GEO:GSM799426, GEO:GSM847106, GEO:GSM844668, GEO:GSM851934, GEO:GSM887456, GEO:GSM888536, GEO:GSM1001493, GEO:GSM1153434, GEO:GSM1153435, GEO:GSM1178508, GEO:GSM1178509, GEO:GSM1181276, GEO:GSM1181278, GEO:GSM1186813, GEO:GSM1186814, GEO:GSM1186815, GEO:GSM1186816, GEO:GSM1186827, GEO:GSM1291149, GEO:GSM1374771, GEO:GSM1374772, GEO:GSM1374773, GEO:GSM1670317, GEO:GSM2124645, GEO:GSM2474989, IARC\_TP53:1417, ICLC:HTL97004, IGRhCellID:OVCAR3, IZSLER:BS TCL 131, KCB:KCB 2006106YJ, KCLB:30161, LiGeA:CCL\_502, LINCS\_LDP:LCL-1522, Lonza:31, MetaboLights:MTBLS150, MetaboLights:MTBLS152, Millipore:SCC257, NCBI\_Iran:C430, NCI-DTP:OVCAR-3, PharmacDB:OVCAR3\_1217\_2019, PRIDE:PXD003105, PRIDE:PXD003668, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304,

Progenetix:CVCL\_0465, PubChem\_Cell\_line:CVCL\_0465, RCB:RCB2135, SKY/M-FISH/CGH:2742, TKG:TKG 0602, TOKU-E:2754, Ubigene:YC-D019, Wikidata:Q54937005

**ID:** CVCL\_0465

**Record Creation Time:** 20250131T202204+0000

**Record Last Update:** 20250131T204022+0000

---

## Ratings and Alerts

No rating or validation information has been found for OVCAR-3.

**Warning:** Discontinued: ICLC; HTL97004

Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Secretome proteome analysis., Omics: Protein expression by reverse-phase protein arrays., Omics: O-glycan profiling., Omics: N-glycan profiling., Omics: Metabolome analysis., Omics: lncRNA expression profiling., Omics: GPI-anchored proteins analysis by proteomics., Omics: Genome sequenced., Omics: Fluorescence phenotype profiling., Omics: Exosome proteome analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep proteome analysis., Omics: Deep exome analysis., Omics: CRISPR phenotypic screen., Omics: CNV analysis., Omics: Array-based CGH., Population: Caucasian., Part of: OCCP ovarian cancer cell line panel., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: ENCODE project common cell types; tier 3., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 1547 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Wen F, et al. (2025) LPCAT3 regulates the proliferation and metastasis of serous ovarian cancer by modulating arachidonic acid. *Translational oncology*, 52, 102256.

Huang J, et al. (2024) BBOX1 mediates metabolic reprogramming driven by hypoxia and participates in the malignant progress of high-grade serous ovarian cancer. *Biochimica et biophysica acta. Molecular cell research*, 1871(8), 119830.

Xu X, et al. (2024) FOXF1 promotes ovarian cancer metastasis by facilitating HMGA2-mediated USP30-dependent S100A6 deubiquitination. *Biochimica et biophysica acta. Molecular basis of disease*, 1871(3), 167633.

Li H, et al. (2024) N6-methyladenosine-modified VGLL1 promotes ovarian cancer metastasis through high-mobility group AT-hook 1/Wnt/?-catenin signaling. *iScience*, 27(3), 109245.

Khetan R, et al. (2024) Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation. *Journal of ovarian research*, 17(1), 156.

Aljardali MW, et al. (2024) Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers. *Cancer research communications*, 4(6), 1495.

Mei B, et al. (2024) All-trans retinoic acid sensitizes epithelial ovarian cancer to PARP inhibition after exposure to cisplatin. *Molecular cancer therapeutics*.

Wu H, et al. (2024) RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter. *Journal of cellular and molecular medicine*, 28(6), e18115.

Kunkel MW, et al. (2024) HTS384 NCI60: The Next Phase of the NCI60 Screen. *Cancer research*, 84(15), 2403.

Mishra AK, et al. (2024) Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer. *Cell reports*, 43(4), 114041.

Nie H, et al. (2024) Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade. *Nature communications*, 15(1), 2853.

Dietrich C, et al. (2024) INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors. *Cancer discovery*, 14(3), 446.

Dong B, et al. (2024) NK Receptor Signaling Lowers TCR Activation Threshold, Enhancing Selective Recognition of Cancer Cells by TAA-Specific CTLs. *Cancer immunology research*, 12(10), 1421.

Xu H, et al. (2024) CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer. *iScience*, 27(7), 109978.

Sottnik JL, et al. (2024) WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. *Cancer research communications*, 4(1), 134.

Han J, et al. (2024) Identification of the biological functions and chemo-therapeutic responses of ITGB superfamily in ovarian cancer. *Discover oncology*, 15(1), 198.

Fox A, et al. (2024) Adipose microenvironment promotes hypersialylation of ovarian cancer cells. *bioRxiv : the preprint server for biology*.

Persenaire C, et al. (2024) VDX-111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression. *Molecular carcinogenesis*, 63(7), 1248.

Sirtos AN, et al. (2024) RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells. *bioRxiv : the preprint server for biology*.

Crump LS, et al. (2024) Targeting Tryptophan Catabolism in Ovarian Cancer to Attenuate Macrophage Infiltration and PD-L1 Expression. *Cancer research communications*, 4(3), 822.